舒泰神1月30日获融资买入2081.25万元，融资余额1.33亿元

Core Viewpoint - On January 30, Shutaishen's stock increased by 0.63% with a trading volume of 395 million yuan, indicating a positive market response to the company's recent performance and activities [1]. Financing Summary - On January 30, Shutaishen had a financing buy-in amount of 20.81 million yuan, with a current financing balance of 133 million yuan, accounting for 1.08% of the circulating market value [2]. - The company had no short selling activity on January 30, with both short selling repayment and selling amounting to 0.00 shares and 0.00 yuan respectively [2]. Company Overview - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and listed on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [2]. - The main revenue sources for Shutaishen include: 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [2]. Financial Performance - For the period from January to September 2025, Shutaishen reported an operating income of 181 million yuan, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million yuan, a year-on-year decrease of 227.71% [2]. Shareholder Information - As of September 30, 2025, Shutaishen had 46,500 shareholders, an increase of 46.97% compared to the previous period, with an average of 9,745 circulating shares per person, a decrease of 31.98% [2]. - The company has cumulatively distributed 771 million yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3]. - Among the top ten circulating shareholders, notable changes include a decrease of 3.45 million shares held by the third-largest shareholder, Xingquan Helun Mixed A, and an increase of 3.39 million shares held by the fifth-largest shareholder, Xingquan Heyi Mixed A [3].